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Abstract
Background: Resistance to taxane-based therapy in breast cancer patients is a major clinical problem that may be
addressed through insight of the genomic alterations leading to taxane resistance in breast cancer cells. In the
current study we used whole exome sequencing to discover somatic genomic alterations, evolving across
evolutionary stages during the acquisition of docetaxel resistance in breast cancer cell lines.
Results: Two human breast cancer in vitro models (MCF-7 and MDA-MB-231) of the step-wise acquisition of
docetaxel resistance were developed by exposing cells to 18 gradually increasing concentrations of docetaxel.
Whole exome sequencing performed at five successive stages during this process was used to identify single point
mutational events, insertions/deletions and copy number alterations associated with the acquisition of docetaxel
resistance. Acquired coding variation undergoing positive selection and harboring characteristics likely to be
functional were further prioritized using network-based approaches.
A number of genomic changes were found to be undergoing evolutionary selection, some of which were likely to
be functional. Of the five stages of progression toward resistance, most resistance relevant genomic variation
appeared to arise midway towards fully resistant cells corresponding to passage 31 (5 nM docetaxel) for
MDA-MB-231 and passage 16 (1.2 nM docetaxel) for MCF-7, and where the cells also exhibited a period of reduced
growth rate or arrest, respectively. MCF-7 cell acquired several copy number gains on chromosome 7, including
ABC transporter genes, including ABCB1 and ABCB4, as well as DMTF1, CLDN12, CROT, and SRI. For MDA-MB-231
numerous copy number losses on chromosome X involving more than 30 genes was observed. Of these genes,
CASK, POLA1, PRDX4, MED14 and PIGA were highly prioritized by the applied network-based gene ranking approach.
At higher docetaxel concentration MCF-7 subclones exhibited a copy number loss in E2F4, and the gene encoding
this important transcription factor was down-regulated in MCF-7 resistant cells.
Conclusions: Our study of the evolution of acquired docetaxel resistance identified several genomic changes that
might explain development of docetaxel resistance. Interestingly, the most relevant resistance-associated changes
appeared to originate midway through the evolution towards fully resistant cell lines. Our data suggest that no
single genomic event sufficiently predicts resistance to docetaxel, but require genomic alterations affecting multiple
pathways that in concert establish the final resistance stage.
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Background
Resistance to taxane therapy in breast cancer patients
remains a major clinical problem with approximately 20 %
of neo-adjuvant or adjuvant taxane treated patients experi-
encing disease recurrence with subsequent death from
breast cancer. We here hypothesize that characterization of
taxane resistance-associated molecular alterations and iden-
tification and validation of putative predictive markers will
have the potential to result in more effective use of taxanes,
with improved survival and reduced toxicities and costs.
Currently, only a few predictive biomarkers are used in the
clinical management of breast cancer. Among them is the
estrogen receptor, used to predict sensitivity to endocrine
therapy, and HER2 expression, used to predict sensitivity to
HER2-targeting drugs, e.g. Trastuzumab (Herceptin) and
Lapatinib. More recently, TOP2A gene aberrations were
related to anthracycline sensitivity [1, 2] and two recent
meta-analyses concluded that TOP2A aberrations predict
an incremental benefit from anthracyclines [3, 4].
Taxanes (docetaxel, paclitaxel) are mitotic inhibitors and
play a key role in the treatment of primary and advanced
breast cancer [5–8]. Taxanes induce a mitotic block by
binding to the beta-tubulin subunit of the microtubules,
thereby preventing their disassembly [9]. However, resist-
ance to taxanes may appear during or after taxane therapy,
leading to increased patient morbidity and mortality. Prior
studies in taxane resistance have particularly focused on ex-
pression of the ABCB1 product permeability-glycoprotein
(Pgp), which belongs to the superfamily of ATP-binding
cassette (ABC) transporters [10]. Pgp is a xenobiotic drug
efflux pump, and its overexpression has been extensively
investigated as a predictor of multidrug resistance (MDR)
to chemotherapeutics including taxanes [10, 11]. A meta-
analysis of breast cancer, including 31 studies (>1200
patients), reported that approximately 40 % of all breast
tumors expressed Pgp and Pgp expressing tumors were
three times more likely to be chemotherapy-insensitive
[11]. In addition to Pgp, several other ABC transporters
reportedly confer an MDR phenotype [10], but an under-
standing of the mechanisms underlying the development of
resistance to taxane remains incomplete.
Recently, analyses of the whole genome of breast tumors
have been presented. Applying next-generation sequencing
techniques, new breast cancer-related genes have been sug-
gested [12, 13], and data obtained from various experimen-
tal platforms (DNA, RNA, protein) have been combined in
an attempt to create integrated molecular characterizations
of breast cancers [14]. In addition, several studies have suc-
cessfully applied next generation sequencing to discover
novel mechanisms of cancer chemotherapy resistance, and
to elucidate tumor cell progression and survival properties
during chemotherapy exposure [15–19]. To date, limited
genomic alterations characterizing the development of
taxane-resistant cancer cells have been identified. Here, we
applied whole exome sequencing to in vitro breast cancer
models of docetaxel resistance to acquire insight into
resistance-related genomic changes and the process of
resistance development. We sequenced the exome of two
breast cancer cell lines (MCF-7 and MDA-MB-231) and
their resistant sub-lines, which were isolated during sev-
eral steps of successive development of resistance. We
hypothesize that studying this evolution of docetaxel
resistance will reveal genomic events that play important
roles for the development of a docetaxel-resistant pheno-
type. Eventually, some of these mutations, either individu-
ally or as a panel, may potentially serve as predictive
biomarkers of taxane therapy.
Methods
Cell lines
Resistant breast cancer cell lines were developed as previ-
ously described [20]. In brief, resistant breast cancer cells
were developed by exposing cells to gradually increasing
concentrations of docetaxel (Sanofi-Aventis, Hoersholm,
Denmark) [20]. Cells were grown in complete medium
(Dulbecco’s modified Eagle’s medium (DMEM) including
L-glutamine, supplemented with 5 % fetal calf serum (FCS)
as well as 1 % non-essential amino acids for the MCF-7
cells and 10 % FCS for the MDA-MB-231 cells; all obtained
from Life Technologies, Carlsbad, USA) in a humidified at-
mosphere containing 5 % CO2 at 37 °C. For maintenance
of resistant cells, docetaxel (MCF-7: 65 nM; MDA-MB-231:
150 nM) was added to the complete medium. Cell line
identity was verified by the IdentiCell Cell Line Authentica-
tion method (Aarhus University Hospital, Denmark). The
parental cell lines (MCF-7PAR and MDAPAR), four sub-lines
(MCF-7SUB and MDASUB) isolated from each of the two
cell lines during development of resistance, and the final
resistant cell lines (MCF-7RES-65nM and MDARES-150nM)
were further characterized (Tables 1 and 2).
Characterization of cell lines
Docetaxel cytotoxicity was assessed using tetrazolium-
based semiautomated colorimetric (MTT) assay as previ-
ously described [21]. Cells were plated and exposed to
docetaxel as previously described [20]. Cell viability was
calculated in percent compared to untreated control cells.
A minimum of three independent experiments was per-
formed for each of the parental cell lines, sub-lines and final
resistant cell lines.
Stability of the resistant phenotype of the final resist-
ant cell lines was investigated by MTT assay following
one month of docetaxel withdrawal.
Cell growth was investigated by crystal violet assay.
Briefly, on day 0, cells were seeded in 96 well microtiter
plates (identical assays of 7000 and 10 000 cells/well,
respectively) and one plate per day was stained on days 2–
7; the assay was then performed as previously described
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Table 1 Evolution of docetaxel resistance in MCF-7 cells
Docetaxel concentration Passage numbers Days at given concentrationa Subpopulation for analysis Doubling time (Days)
0 (Parental cells) - - MCF-7PAR 1.3
10 pM 1–3 12
30 pM 4–6 13
90 pM 7–9 18
270 pM 10–12 17 MCF-7SUB-0.27nM 1.9
810 pM 13–15 12
1.2 nM 16–18 69 MCF-7SUB-1.2nM 1.8
1.8 nM 19–21 25
2.25 nM 22–24 13
2.8 nM 25–27 19
3.5 nM 28–30 20
5 nM 31–33 18
7.5 nM 34–36 12 MCF-7SUB-7.5nM 1.9
15 nM 37–39 13
30 nM 40–42 16
45 nM 43–45 24 MCF-7SUB-45nM 1.8
55 nM 46–48 26
65 nM 49- MCF-7RES-65nM 1.4
aNumbers in bold indicate concentration levels at which the cells took more than the average 20 days per concentration step to recover and go through
3 passages
Table 2 Evolution of docetaxel resistance in MDA-MB-231 cells
Docetaxel concentration Passage numbers Days at given concentrationa Subpopulation for analysis Doubling time (Days)
Parental - - MDAPAR 1.1
10 pM 1–3 16
30 pM 4–6 13
90 pM 7–9 18
270 pM 10–12 14 MDASUB-0.27nM 1.4
810 pM 13–15 20
1.2 nM 16–18 14
1.8 nM 19–21 23
2.25 nM 22–24 16
2.8 nM 25–27 13
3.5 nM 28–30 18
5 nM 31–33 22 MDASUB-5nM 1.6
15 nM 34–36 35 MDASUB-15nM 2.8
45 nM 37–39 25
60 nM 40–42 28
80 nM 43–45 25
100 nM 46–48 18 MDASUB-100nM 1.0
120 nM 49–51 26
150 nM 52- MDARES.150nM 1.0
aNumbers in bold indicate concentration levels at which the cells took more than the average 20 days per concentration step to recover and go through
3 passages
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[20]. The doubling time was calculated for cells in exponen-
tial growth phase using the equation N =N0 x e
kt assuming
proportionality between absorbance and cell number.
These analyses were conducted three times and the result
from one representative experiment is reported.
Cell cycle was analyzed as follows: In 6 well plates 20E4
cells/well or 15E4 cells/well were seeded of the MCF-7 cell
lines and MDA-MB-231 cell lines, respectively. Cells were
cultured for 3 days in their standard growth medium
supplemented with proper concentration of docetaxel for
the resistant cell lines. Cell cycle analysis was performed
using the Nucleocounter system NC-250TM Two step cell
cycle analysis kit (Chemometec, Allerød, Denmark). In
brief, cells were washed in PBS and stained with 250 μl
lysis buffer containing DAPI (10 μg/ml) for 5 min at 37°
and thoroughly resuspended. Cells were stabilized by
adding 500 μl stabilization buffer and cellular fluorescence
quantified. Cell cycle distribution was calculated using the
NC-250TM Nucleoview software. These analyses were
conducted three times and the result from one representa-
tive experiment is reported.
DNA purification and sequencing
DNA was purified using Qiagen DNeasy Blood & Tissue
Kit (Product #69604, Qiagen Nordic, Copenhagen,
Denmark) according to the manufacturer’s instructions.
The purity of the DNA was analyzed using a NanodropTM
spectrophotometer.
Library construction and whole exome sequencing
Extracted DNA that passed quality control (undegraded,
quantity > 3 μg) was selected for library construction.
Agilent SureSelect Human All Exon Kit 50 Mb (Agilent
Technologies, Santa Clara, USA) was used for exome
enrichment and generated Illumina sequencing libraries
according to the manufacturer’s protocols (Illumina, San
Diego, USA). 1 to 2 μg of genomic DNA was sheared
into 200 nt fragments on average by the Covaris S2 sys-
tem (Covaris Inc, MA, USA), after which the DNA frag-
ments were subsequently end-repaired, extended with
an ‘A’ base on the 3′ end, ligated with indexing-specific
paired-end adaptors followed by pre-capture PCR. Pre-
pared libraries were hybridized for 24 h with biotinylated
oligo RNA baits, and enriched with streptavidin-coated
magnetic beads. Cluster generations of the libraries were
then performed on Illumina cBot following the manufac-
turer’s recommended protocols (TruSeq PE Cluster Kit
v3; Illumina). Finally, the clustered libraries were trans-
ferred onto HiSeq 2000 sequencers (Illumina) for 2 ×
90 nt paired-end sequencing.
Pre-processing of sequencing reads
Sequencing read quality was inspected using the FastQC
software [22]. Adapter removal and read trimming were
performed using Trimmomatic [23]. Sequencing reads
were trimmed from the end (base quality less than Q20)
and filtered by length (less than 25). Reads were mapped
and aligned against the reference genome (build
GRCh37) using Novoalign version 2.08.02 from Novo-
craft [24]. The alignment was sorted and then filtered to
obtain a minimum mapping quality of Q30. This was
performed using Samtools version 0.1.13 [25]. Reads
mapping off target were removed with BedTools version
2.11.2 [26]. Duplicate reads were then removed using
MarkDuplicates.jar from Picard’s suite of tools version
1.66 [27] and indexed using Samtools version 0.1.13. A
local realignment around insertions and deletions was
performed followed by a base quality score recalibration.
Both steps were performed using the GATK Toolbox
version 2.4-9 [28]. Finally GATK was used to left align
insertions/deletions in the filtered, realigned and base
quality score recalibrated BAM files.
Variant detection, annotation and functional impact
predictions
We applied a multi-sample calling strategy using Unified-
Genotyper [29] to call single nucleotide variation (SNVs),
insertions and deletions. Raw SNV calls were filtered using
variant quality score recalibration, whereas a basic filtering
approach was employed on insertions and deletions.
Copy number alterations (CNAs) were identified using
CONTRA (Copy Number Targeted Resequencing Ana-
lysis, [30]), - a tool specifically designed to detect CNAs
from targeted re-sequencing data, ranging from smaller
regions to whole-exome capture data. Copy number
gains and losses in a region were estimated using base-
level log-ratios and significance assigned using the null
distribution of log-ratios as further detailed in [30].
CNAs were inferred for the resistant stages using the
parental and any preceding stage as reference. We used
Ensembl Variant Effect Predictor (version 2.8) for the
annotation of detected mutations, and obtained informa-
tion regarding the gene in which the mutation resides,
the associated protein, and the protein domain poten-
tially affected, among others. Also, SIFT [31] and
PolyPhen [32] were used to assess how conserved the
protein regions were in which the mutations occurred,
indicating functional impact or possible impaired protein
function. CNAs were annotated by querying Ensembl’s
databases (v73), thereby providing information regarding
genes overlapping a detected amplified or deleted region.
In addition, information regarding previously obtained
gene expression alterations, as described in [20], for final
resistant cells was associated with identified CNAs.
Variant classification
An identified mutation was classified as acquired in a
given resistant subline if it had not been called in the
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stage preceding it. Also, the preceding stage should have
a read depth greater than four at the given position, and
there should be no evidence of the alternative allele, i.e.,
the number of reads supporting the alternative allele
should be zero. This allowed us to select mutations with
confidence they were acquired in progressive stages and
had not been seen before in assessable (sufficient se-
quence depth) regions. A similar approach was used for
the CNAs. Because all CNAs are inferred with preceding
stages as reference, they are per definition acquired. As a
cell line progresses towards a fully resistant stage, it ac-
quires and accumulates mutations and CNAs, but far
from all variants are equally functionally important, and
only a fraction of the variants are likely to play a role in
the development of resistance to docetaxel. Several strat-
egies were employed to narrow down the list of muta-
tions (and genes) of interest for inclusion in further
downstream analysis primarily focusing on the idea that
variation under selection would provide a functional ad-
vantage to cell survival. A variant was inferred to be
under selection if it was acquired in a given stage and
then also seen in the following stages as well as in the
final resistant stage. Mutation events that were not seen
in subsequent stages were not considered in the analysis.
Thus only accumulating events were considered, and
such variants denoted as acquired selective-events. In
addition, identified acquired selective-events were
grouped into three classes according to their likely func-
tional character: Class A variants were regarded as
likely-functional events and included splice donor and
splice acceptor variants, stop gain and stop loss variants,
frameshift variants, initiator codon variants, transcrip-
tion factor (TF) binding site variants, missense variants
(if predicted to be deleterious by either SIFT and/or
PolyPhen or if located in a protein domain). Class B var-
iants encompassed events wherein the impact was more
difficult to determine without further functional studies,
and included inframe insertions and deletions, missense
variation of predicted benign character, splice region var-
iants, incomplete terminal codon variants, mature
microRNA (miRNA) variants, nonsense-mediated decay
(NMD) transcript variants and various types of regula-
tory variants. Finally, Class C variants contained those
variants likely considered benign or ‘silent’, although we
cannot completely exclude a potential functional impact
of such variants on the protein product, but simply as-
sume a functional character is less likely or would need
significant additional evidence to be credible. This class
included synonymous variants, stop retained variants, 5
prime UTR variants, 3 prime UTR variants, non-coding
exon variants, nc-transcript variants, intron variants, up-
stream and downstream gene variants and intergenic
variants. Figure 1 gives an overview of the classification
procedure just described.
Gene expression profiling
Gene expression analysis (microarrays) has previously
been performed on the cell lines by methods described
elsewhere [20], that included the parental and final
resistant stages (MCF-7PAR/MCF-7RES-65nM and MDA-
PAR/MDARES-150nM). We correlated available gene
expression profiles for these stages with identified copy
numbers to search for CNAs that might explain changes
observed in the expression of certain genes in the final
resistant cells (MCF-7RES-65nM and MDARES-150nM).
Relating selective events to cancer hallmarks
Cancer hallmarks [33] comprise a list of acquired bio-
logical changes defining cancer as such. Here, we used
literature curation to categorize genes carrying a select-
ive event according to the eleven cancer hallmark cat-
egories: Activating invasion and metastasis (H1),
Enabling replicative immortality (H2), Evading growth
suppressors (H3), Evading Immune destruction (H4),
Genome instability and mutation (H5), Inducing angio-
genesis (H6), Reprogramming energy metabolism (H7),
Resisting cell death (H8), Sustaining proliferative signal-
ing (H9), Tumor-promoting inflammation (H10) and
Tumor microenvironment (H11).
For a subset of the detected variation, we assessed the
association of the corresponding genes and the eleven
cancer hallmarks. This subset included Class A and B
variants plus CNA events that correlated with expression
and included 916 genes in total, of which 396 had previ-
ously been associated with breast neoplasm, and these
were then mapped to the hallmark classes.
Random walk-based gene prioritization
Motivated by the assumption that potential new taxane
resistance-associated genes might harbor characteristics
similar to those already found to cause resistance to tax-
anes, we used a network-based gene prioritization strategy
implemented in the Cytoscape plugin GPEC [34]. GPEC
scores and ranks genes based on their functional similarity
with known resistance genes identified by literature cur-
ation, as previously described [Ehlers et al, unpublished ob-
servations]. Only Class A mutations (see above) and CNAs
that associate with a changed expression of the gene were
further ranked with GPEC. We ranked genes in each stage
as well as across all stages to identify the potentially most
important genes for a given stage as well as the most im-
portant genes overall.
Gene stage enrichment analysis
Online enrichment tools were applied in order to iden-
tify co-functioning genes in each stage with Class A mu-
tations or CNAs and annotate these to biological
functions. Genes in each stage of the MCF-7 and
MDA-MB-231 cell lines were analysed using DAVID
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Bioinformatics Resources 6.7 [35, 36] and GOrilla
[37, 38]. The resulting groups of genes identified by
DAVID or GOrilla were only considered important if
the enrichment score for a gene set was ≥ 1. Redun-
dant GO terms were simplified using REVIGO [39]
and AmiGO 2 [40]. Similar biological annotations
were evaluated and redundant annotations were
consolidated.
Results and discussion
In vitro model of docetaxel resistance
Two different human breast cancer cell lines, MCF-7
and MDA-MB-231, which are widely used as models for
hormone-dependent and -independent human breast
cancer, respectively, were cultured in the presence of in-
creasing concentrations of docetaxel. The development
process and investigated subpopulations are outlined in
Fig. 1 Workflow used in the interpretation and classification of detected mutations
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Tables 1 and 2. A total of 17 (MCF-7) and 18 concentra-
tions (MDA-MB-231) were applied to the cells, and both
cell lines spent an average of 20 days at each concentra-
tion step through 3 successive passages. For MCF-7, we
observed temporary growth arrest at 1.2 nM docetaxel
(69 days) followed by normal growth rate at concentra-
tions above 1.2 nM. MDA-MB-231 cells grew slower at
15 nM docetaxel, but did not arrest growth at any time.
For MCF-7, resistance development was stopped at 65
nM docetaxel (MCF-7RES-65nM), and for MDA-MB-231,
the final concentration was 150 nM (MDARES-150nM).
MCF-7RES-65nM and MDARES-150nM, their respective par-
ental cell lines and four additional sub-lines per cell line
(MCF-7SUB and MDASUB), isolated during development
of resistance, were further characterized.
Docetaxel cytotoxicity
Culturing of cells with continuous exposure to increasing
concentrations of docetaxel induced resistance to the drug.
As previously described, both MCF-7 and MDA-MB-231
cells showed a biphasic response pattern when exposed to
docetaxel, with their final resistant sub-lines being signifi-
cantly more resistant both in a first phase at lower
docetaxel concentrations, and in a second phase at higher
concentrations [20]. The sensitivity of selected sub-lines
isolated during development of resistance was investigated
and the survival of each of the sub-lines was calculated as
the ratio of surviving cells in each sub-line compared to the
corresponding parental cell line. The results are depicted in
Fig. 2a-d. In MCF-7, when exposing cells to high concen-
trations of docetaxel (20–50 μM) resistance was observed
as early as in the first investigated sub-line (MCF-7SUB-
0.27nM) as well as in the rest of the investigated cells (Fig. 2a).
At lower concentrations of docetaxel (0.1–5 μM), however,
only sub-lines that had been exposed to higher concentra-
tions of the drug (MCF-7SUB-45nM and MCF-7RES-65nM)
were resistant compared to the parental MCF-7 cell line
(Fig. 2b). In MDA-MB-231, resistance to docetaxel
developed gradually as cells were exposed to increasing
concentrations of the drug; this applies to both low and
Fig. 2 Sensitivity of parental and reistant sub lines to docetaxel. The survival ratio of MCF-7 (a, b) and MDA-MB-231 (c, d) sub-lines compared
to corresponding parental cell lines (MCF-7PAR/ MDAPAR). Cells were exposed to docetaxel at the indicated concentrations for 72 h and survival
was estimated using an MTT assay. Values are expressed as relative values compared to the parental cell lines. Mean values of three independent
experiments ± SEM are shown
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high concentrations of docetaxel (Fig. 2c and d). MDASUB-
0.27nM did not differ from parental MDA-MB-231 cells with
regard to docetaxel sensitivity (Fig. 2c and d).
Stability of the final resistant phenotype was confirmed
as both MCF-7RES-65nM and MDARES-150nM showed no
change in sensitivity to docetaxel following one month of
culturing without docetaxel exposure (data not shown).
This suggests that the phenotypic alterations in sensitivity
to docetaxel are due to genomic alterations.
Growth pattern
The doubling times for parental MCF-7 and MDA-MB-
231 cells plus the derived docetaxel-exposed cell lines
are listed in Tables 1 and 2. For MCF-7, doubling times
increased slightly as cells developed resistance to doce-
taxel. The reported doubling times apply to cells grow-
ing stably at the indicated concentrations. However, as
previously noted, cells went through a period of arrested
growth at 1.2 nM docetaxel. In docetaxel-treated MDA-
MB-231 cells, doubling times first increased, but became
similar to parental cells after MDASUB-15nM.
Cell cycle
The distribution of parental and docetaxel-exposed
MCF-7 sub-clones in the different phases of cell cycle
was also examined (Fig. 3). MCF-7 parental cells and
docetaxel-exposed MCF-7 sub-clones showed similar
distributions, with the majority of the cells in G1
(Fig. 3a). For MDA-MB-231 cells, some clear differences
in the fractions were observed when compared to the
parental cells. For sub-lines MDASUB-5nM and MDASUB-
15nM considerably fewer cells were in G1 and more cells
were in subG1; this pattern, to a lesser degree, was also
observed in MDASUB-100nM and MDASUB-150nM (Fig. 3b).
The evolution of resistance – an orchestration of events
Between 55,000 and 59,000 single point mutations and
5,800–6,200 indels (Additional file 1: Table S1) were de-
tected in each sub-line sequenced indicating a high bur-
den or initial variation as compared to the human
reference used in the study. The amount of acquired
variation detected in each sub-line was variable and
ranged from a few to just over 560 mutations, with most
variants being acquired in the early phase of resistance
development (MCF-7SUB-0.27nM and MDASUB-0.27nM)
(Tables 3 and 4). Surprisingly, only a small percentage of
variation acquired in a given cell sub-line was actually
carried on to the final resistant stage (Tables 3 and 4).
The majority of acquired genomic variants appeared to
be silent (Tables 5 and 6), and only a small fraction
thereof were classified as likely functional events (variant
Class A, Fig. 1) (Additional file 1). A variable number of
missense mutations were predicted to be deleterious by
SIFT and Polyphen in each sub-line. In both cell lines,
the sub-lines MCF-7SUB-0.27nM, MCF-7SUB-1.2nM, MDA-
SUB-0.27nM, and MDASUB-5nM accounted for the largest
number of deleterious missense mutations in the cat-
egory of acquired selective-events. Mapping of a selected
number of genes to the cancer hallmark categories [33]
revealed that most genes fall into the categories ‘sustain-
ing proliferative signaling’ and ‘activating invasion and
metastasis’ (Additional file 2). SIFT and Polyphen have
been used as major determinants for change in function,
and we believe that change in conserved sequence that
these tools pick up are indicative both of loss and gain
in function. However it has been shown in prior studies
that these tools capture loss-of-function variants better
than gain-of-function variants, and we would like to
point out that some gain of function missense variants
will be missed in the analysis.
Fig. 3 Cell cycle analysis of parental cells and resistant subclones. The bar charts show the distribution of cells in cell cycle phases G2/M, S, G1
and SubG1 for MCF-7PAR and docetaxel resistant subclones (a) and MDAPAR and resistant subclones (b). The resistant subclones were cultured in
the presence of the indicated docetaxel concentrations. Mean values of three independent experiments ± SEM are shown
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In addition to detecting single mutational events, small
insertion and deletions, we also used the exome data to
identify CNAs acquired as a consequence of cell line de-
velopment during docetaxel exposure. While copy num-
ber detection from whole exome sequencing data still
requires further development, several methods have
emerged [30, 41–44]. Here we used CONTRA [30] to
identify regions of amplification or deletion in the cell
line samples. After mapping CNA regions to genes, we
then correlated CNA-genes detected in any sub-line with
the expression profiles of the gene in the final resistant
sub-lines (MCF-7RES-65nM/ MDARES-150nM) compared to
the parental cell lines (MCF-7PAR/ MDAPAR). This ap-
proach made it possible for us to reduce the amount of
false negatives due to insufficient coverage. For instance,
if a CNA event was detected in early stages of resistance
development, but not found in later stages, despite the
fact that the gene in which the CNA event was found
was observed to be up-regulated in the final stage, this
speaks in favor of the CNA still being present at this
stage, but we are just not able to detect it with our ex-
ome data alone. The copy number profiles were very dif-
ferent between the two cell lines. Of primary interest for
the MCF-7 cells were several copy number gains ac-
quired during exposure to increasing concentrations of
docetaxel, most of which resided on chromosome 7, but
also on chromosome 4, 5, 8, 11 and 14. The MDA-MB-
231 sub-lines predominately acquired copy number
losses, primarily on the X chromosome, but also on
chromosome 2, 6, 7, 9, 15 and 21, (Additional file 3).
It should be pointed out that despite the additional
gene expression data, there are still inaccuracies in copy
number analyses that will be expected. For instance,
since many CNAs are smaller than the gene size, these
likely result in alternative transcript isoforms rather than
changing gene expression.
Genomic alterations potentially driving the development
of docetaxel resistance
To further rank and prioritize selected variants consist-
ing of Class A variation and CNAs that correlated with
expression profiles of the corresponding gene, we used a
network-based approach [34] to measure the similarity
of this gene set to genes previously associated with re-
sistance to taxanes in the literature.
For the network-based analysis performed across all
stages, the top five ranked genes were ABCB4, CDC25B,
FES, ACVR1 and RDX for the MCF-7 sub-lines, and JAK2,
CARD11, KDM4C, VWF, CA5B for the MDA-MB-231
sub-lines (Additional file 4). A similar analysis performed
on each sub-line separately revealed the genes potentially
Table 3 The number of acquired and selected variants
detected in the MCF-7 sub-lines
MCF-7 MCF-7 MCF-7 MCF-7 MCF-7
SUB-0.27nM SUB-1.2nM SUB-7.5nM SUB-45nM RES-65nM
Acquired
SNVs
506 179 140 181 253
Selected
SNVs
166 84 27 50
Acquired
Indels
109 40 28 29 43
Selected
Indels
31 11 5 14
Table 4 The number of acquired and selected variants
detected in the MDA-MB-231 sub-lines
MDA MDA MDA MDA MDA
SUB-0.27nM SUB-5nM SUB-15nM SUB-100nM RES-150nM
Acquired
SNVs
567 363 361 409 242
Selected
SNVs
174 71 14 42
Acquired
Indels
103 28 31 23 34
Selected
Indels
29 6 7 13
Table 5 Variant types: acquired and selected variants in MCF-7
sub-lines
Consequence MCF-7 MCF-7 MCF-7 MCF-7 MCF-7
SUB-0.27
nM
SUB-1.2
nM
SUB-7.5
nM
SUB-45
nM
RES-65
nM
3 prime UTR variant 26 6 2 2 29
5 prime UTR variant 6 6 1 2 21
NMD transcript variant 70 33 3 14 128
TF binding site variant 0 0 0 0 0
Downstream gene variant 169 85 29 38 236
Feature elongation 29 2 8 22 20
Feature truncation 63 38 7 18 75
Frameshift variant 0 1 0 0 0
Inframe insertion 0 0 0 0 0
Intron variant 618 228 70 136 656
Mature miRNA variant 0 0 0 0 0
Missense variant 44 55 0 12 85
Nc transcript variant 182 89 12 58 203
Non coding exon variant 45 36 3 13 75
Regulatory region variant 27 13 5 12 54
Splice acceptor variant 0 0 0 0 12
Splice region variant 12 5 1 6 17
Stop gained 0 4 0 0 10
Synonymous variant 35 24 3 5 68
Upstream gene variant 95 66 13 38 195
Total 1421 691 157 376 1884
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most important for resistance development in the sub-lines
and resistant stage in MCF-7 (Fig. 4a) and MDA-MB-231
(Fig. 4b) (Additional files 4 and 5). The enrichment analyses
of the genes in each developmental stage for the MCF-7
and MDA-MB-231 cell lines identified relevant groups of
genes were annotated for MCF-7SUB-1.2nM and MCF-7RES-
65nM (Table 7), while enriched groups in the MDA-MB-231
cell line were identified for MDASUB-5nM and MDARES-
150nM (Table 8). Thus, at a general level genomic change
occuring midways in the acquisition of docetaxel resistance
and in the resistant stage of both cell lines were identified
to be associated with various biological annotations. In the
early phase of resistance development (MCF-7SUB-0.27nM
and MDASUB-0.27nM) the acquisition of a number of dele-
terious mutations as well as a single CNA event in the
MDA-MB-231 sub-line was observed. Of particular interest
was the acquisition of a number of single point mutations
in genes such as RYR2, DDX10, CDH23, ANXA8, CHD3,
RHPN2 and HLA-DRB5 as well as a copy number loss in
HADHB. These genes are observed to code for proteins
having several interactions with proteins already associated
with taxane resistance. The genes RYR2, CDH23 and
RHPN2 are altered in both cell line model systems. While
the RYR2 gene has acquired a deleterious point mutation
in MCF-7SUB-0.27nM, it is observed to be down-regulated in
MDARES-150nM. The CDH23 gene is altered twice in the
MCF-7 cell line in that a deleterious point mutation is
acquired in early stage (MCF-7SUB-0.27nM) of resistance
development followed by a copy number loss in the gene in
the final resistant stage (MCF-7RES-65nM) where we also
measured the gene as down-regulated. The gene is down-
regulated in the MDARES-150nM as well. The CDH23 pro-
tein interacts with the product of ATP2B2, which have been
associated with resistance to paclitaxel, where inhibition of
ATP2B2 leads to increased sensitivity towards the action of
paclitaxel [45]. Finally, RHPN2 is encoding the Rho GTPase
binding protein 2 and interacts with the products of SFN
and HNF4A, which have been associated with resistance to
taxanes. A deleterious point mutation is observed in the
RHPN2 gene in MDASUB-0.27nM, while the same gene is
observed to be down-regulated in MCF-7RES-65nM,
strengthening the hypothesis of a role for this gene in the
development of taxane resistance.
Midway through resistance development (MCF-7SUB-
1.2nM and MDASUB-5nM), the acquisition of a number of
CNAs was observed in both model systems. The MCF-
7SUB-1.2nM had acquired several copy number gains on
chromosome 7, which involved the ABC transporters genes
ABCB1 and ABCB4. The ABCB1 gene, also known as
MDR1, encodes Pgp, and is to date the best characterized
and understood chemotherapy efflux transporter [46, 47].
Pgp expression has been correlated with resistance to tax-
anes and has been extensively studied in breast carcinomas
[11]. We recently confirmed that upregulation of MDR1
mRNA and the corresponding Pgp is a major resistance
mechanism in docetaxel-resistant breast cancer cells in
vitro [20]. Also of interest were copy number gains
acquired in the genes DMTF1, CLDN12, CROT, and SRI,
all located on chromosome 7. Though difficult to deter-
mine with our exome data, it is likely that a subset of these
copy number gains are truly just one larger regional gain
acquired on chromosome 7, which coincides with the tem-
porary growth arrest observed in these cells as mentioned
previously. Interestingly, upregulation of DMTF1, CLDN12,
CROT, and SRI together with upregulation of other genes,
such as ASK, CDK6, MGC4175 and MCM7, have previ-
ously been detected in MDR1-positive taxane-resistant
ovarian cancer cell lines [48]. Amplification of this particu-
lar region on chromosome 7q, as seen in our study, has
been seen in other studies and suggested as a fundamental
mechanism of acquired resistance to taxanes [49]. In our
study, this amplified region also included cell-cycle genes
such as CDC25B, SMC3, AKAP9, and DBF4, as well as the
unknown transmembrane protein C7orf23 (TMEM243).
Overexpression of C7orf23 has been associated with resist-
ance to paclitaxel [50]. Other observations made in the
MCF-7SUB-1.2nM cell line worth mentioning included a copy
Table 6 Variant types: acquired and selected variants in
MDA-MB-231 sub-lines
Consequence MDA MDA MDA MDA MDA
SUB-0.27
nM
SUB-5
nM
SUB-15
nM
SUB-100
nM
RES-150
nM
3 prime UTR variant 25 8 1 3 28
5 prime UTR variant 6 7 1 0 14
NMD transcript variant 68 27 4 20 115
TF binding site variant 1 0 0 0 0
Downstream gene variant 197 97 14 40 361
Feature elongation 47 11 18 30 48
Feature truncation 59 14 0 13 29
Frameshift variant 0 0 0 1 0
Inframe insertion 1 0 0 0 0
Intron variant 741 224 51 97 769
Mature miRNA variant 0 0 0 1 0
Missense variant 18 43 4 9 130
Nc transcript variant 202 78 16 30 228
Non coding exon variant 57 37 7 5 74
Regulatory region variant 32 11 1 8 42
Splice acceptor variant 0 0 0 0 0
Splice region variant 22 15 1 2 45
Stop gained 0 2 0 0 9
Synonymous variant 60 30 0 16 61
Upstream gene variant 169 62 5 17 170
Total 1705 666 123 292 2123
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Fig. 4 Genes with a Class A mutation or CNA in each stage in the MCF-7 (a) and MDA-MB-231 (b) cell lines. Genes involved in transport are
marked in red, while kinases are marked in orange. Shaded grey are genes where mutations have accumulated from prior stages
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number gain in IRF9 as well as a copy number loss in
CFL1. Overexpression of this IRF9 has been associated with
resistance to paclitaxel [51] and a link between CFL1
expression and taxane resistance has been suggested [52].
In addition, CNAs were observed in several microtubule
dynamic associated genes including gains of SEMA3E,
ADAM22, AKAP9, SEMA3A and loss of SMURF1, NTN1,
CFL1, and CDC25B, and a deleterious point mutation was
detected in CUL7 which is also involved in microtubule dy-
namics [53]. In particular, the products of CFL1, CDC25B,
and SMURF1 are highly interacting with proteins encoded
by genes with a known association to taxane resistance.
In MDASUB-5nM, a larger fraction of genes located on
chromosome X acquired a copy number loss that was cor-
related with down-regulated genes in MDARES-150nM. The
copy number losses on chromosome X included 39 genes
(Additional file 4), of which several were associated with
development of taxane resistance by the network-based
analysis. Interestingly, one of these genes, POLA1, has been
identified as a microtubule-binding and -modulating pro-
tein [54], and three SNPs in PRDX4 have been associated
with docetaxel clearance [55]. Among the 39 genes, not
highly ranked, but still of interest due to their functional
role of their protein products in the cell, were DDX3X,
involved in chromosome segregation, TBL1X, involved in
spindle microtubule, IQGAP1, involved in stabilization of
the microtubules, PPP2R3B, involved in cell cycle arrest,
and RPS6KA3, involved in the cell cycle. Although it is not
possible to determine with our exome data, it is likely that
the copy number losses found on chromosome X are actu-
ally due to the acquisition of one larger regional loss of the
chromosome, an event that might be a key driver of the de-
velopment of docetaxel resistance.
In sub-lines exposed to higher concentrations of doce-
taxel (7.5nM–15nM) a small number of single point mu-
tations of Class A together with several CNAs were
observed in the cells. In MCF-7SUB-7.5nM, copy number
losses were observed in CDS1, SLC25A13, ATP5SL,
E2F4, PPIE, GPAM, AP4M1 and ZZEF1, and copy num-
ber gains were seen in LPCAT1 and ZFYVE26. Of par-
ticular interest was the loss of the E2F4 gene, which
encodes a transcription factor and is primarily involved
in growth arrest, together with members of the Rb fam-
ily. E2F4 has also been proposed to play a regulatory role
in cellular survival during chemotherapeutic treatment
Table 7 Annotation of genes with Class A mutation or CNAs in
MCF-7 sub-lines
MCF-7 MCF-7 MCF-7 MCF-7 MCF-7
SUB-0.27
nM
SUB-1.2
nM
SUB-7.5
nM
SUB-45
nM
RES-65
nM
Cell motility Chromatin
modification
RCBTB1,
BRPF3, TLK1,
TRRAP
CFL1, SEMA3C,
NTN1, ACVR1
Negative regulation
of signal transduction
RGS1, SMURF1,
GRB14, ACVR1
Cell morphogenesis
CFL1, SEMA3A, NTN1
Neural crest cell
development
CFL1, SEMA3C, ACVR1
Axon guidance
SEMA3E, CFL1, SEMA3C,
SEMA3A, NTN1
Mitotic cell cycle process
DBF4, AKAP9, ABCB1,
CUL7, CDC25B, ACVR1, CFL1
Table 8 Annotation of genes with Class A mutation or CNAs in MDA sub-lines
MDA MDA MDA MDA MDA
SUB-0.27nM SUB-5nM SUB-15nM SUB-100nM RES-150nM
Chromatin modification Nucleotide-binding Protein dimerization activity
MSL3, KDM6A, PHF16, KDM4C, RBBP7 ABCB1, JAK2, RIOK1, CDK16,
CDK14, PRKX
NOTCH2, VWF, SLC11A1, DPP4
Purine nucleoside binding, adenyl nucleotide
binding, atp-binding
T cell activation
EPHA5, RPS6KA3, ABCA9, DDX3X, UBA1, MAPK13,
CASK, CTPS2, VARS, PRPS2, CLCN4
CARD11, SLC11A1, DPP4
Kinase Transport
EPHA5, RPS6KA3, MAPK13, SH3KBP1, CASK, PRPS2 SLC11A1, CACNA1I, MFI2,
CACNA2D3, AQP7, AQP3
Regulation of transcription from RNA polymerase
II promoter
CASK, MED14, RBBP7, TBL1X
Transport
CLCN4, CCDC64, AP1S2, CASK, ABCA9, ATP5J, APOO
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in that it might modulate the predisposition of cells to
undergo drug-induced apoptosis [56]. We found >20 in-
teractions between the E2F4 protein known taxane re-
sistance genes. In MDASUB-15nM, we observed copy
number gains in the ABCB1 and ADAM22 genes similar
to that in the MCF-7SUB-1.2nM. The copy number gains
observed in these genes were not detected in the final
stage (MDARES-150nM), but the fact that the genes were
also observed as upregulated in MDARES-150nM supports
the fact that the copy numbers are still present at this
stage. In addition, a copy number gain was observed in
the JAK2 gene that encodes a tyrosine-protein kinase.
Previously, increased expression of JAK2 has been asso-
ciated with drug resistance in ovarian cancer [57], and
differential expression of JAK2 has been associated with
taxane resistance in the OC3/TAX300 cell line [58].
For the cell line stages MCF-7SUB-45nM and MDA-
SUB-100nM, a few genomic changes were of special
interest. In the MCF-7SUB-45nM, these included copy
number losses in HTATIP2, involved in induction of
apoptosis, and PDCD2L, involved in the cell cycle. In
MDASUB-100nM, a missense mutation (chr7:128587374_G/A)
was discovered in IRF5 that encodes the interferon regula-
tory factor 5, a transcription factor involved in the Toll-
like receptor signaling pathway. Another member of the
interferon regulatory factor family (IRF9), in which we
found a copy number gain in MCF-7SUB-1.2nM, has been
associated with paclitaxel response in that upregulation of
IRF9 may be associated with resistance to paclitaxel, and
suggested as a potential surrogate marker of response [51].
Conclusions
In this study, the use of in vitro grown human breast cancer
cell lines allowed investigation of genomic alterations dur-
ing multiple steps in the process towards a docetaxel-
resistant phenotype. Variations were prioritized for func-
tional changes as well as those that accumulate over stages
of acquiring resistance. A useful extension of this paradigm
would be to conduct deeper sequencing in order to exam-
ine increasing proportions of resistant sub-clones. In our
study, the model system allowed us to identify a number of
genomic variations that are consistent with prior know-
ledge in taxane resistance, and additionally numerous novel
genomic variations that were associated with the develop-
ment of docetaxel resistance. The main conclusion arising
from these data is that no single genomic biomarker
adequately predicts resistance to docetaxel, but rather
requires a panel of markers covering several pathways in-
volved in docetaxel resistance. Specifically, we have identi-
fied a number of genetic variations in genes involved in
drug transport, microtubule dynamics and cell cycle regula-
tion. A corollary of our observations is that exposure of
cells to toxic agents can induce acquisition of stable gen-
omic traits that reduce the effects of these agents,
effectively providing a resistance-associated gene pool to tu-
mors. The importance of the disclosed genomic variations -
and the fact that docetaxel-resistant cells demonstrated dis-
tinct and biologically-relevant DNA aberrations - is that ac-
quisition of docetaxel resistance in clinical breast cancer
also is a stable condition that will prevent beneficial effects
upon subsequent exposure to the same drug, i.e. repeated
docetaxel exposure to patients who relapsed on adjuvant
docetaxel treatment. We therefore propose that a set of pri-
oritized findings from our study should be examined at the
genomic level in resistant tumors.
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across selected genes detected in the MCF-7 sub-lines. Sheet 2: Same as
sheet 1, but with data for the MDA-MB-231 sub-lines. (XLSX 73 kb)
Additional file 5: Sheet 1: Contains a list of genes included in the
GPEC analysis performed on selected genes in each stage (sub-line).
Data shown for both cell lines: MCF-7 and MDA-MB-231. Also, a literature-
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